Parateck to acquire Optinose and with it Xhance (fluticasone propionate).

Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product Xhance (fluticasone propionate). The transaction value is up to $330 million, with consideration payable to shareholders of up to $14 per share, including the payment of contingent value rights (CVRs) tied to future commercial milestones. This acquisition expands Paratek's commercial portfolio beyond its flagship antibiotic, Nuzyra (omadacycline), and strengthens its position as a multi-product company focused on innovative specialty therapies for primary care providers and specialists, addressing important medical health threats.